Keywords: |
unclassified drug; genetics; cancer recurrence; drug withdrawal; treatment duration; recurrence risk; letter; polymerase chain reaction; clinical practice; phenotype; protein tyrosine kinase; chronic myeloid leukemia; protein tyrosine kinase inhibitor; cancer regression; immunology; immune response; immunogenicity; diagnosis; cytotoxic t lymphocyte; scoring system; remission; remission induction; bcr abl protein; drug therapy; leukemia, myelogenous, chronic, bcr-abl positive; meta analysis; fusion proteins, bcr-abl; predictive value; protocol compliance; procedures; breakpoint cluster region protein; humans; human; male; female; digital polymerase chain reaction; bcr-abl1 fusion protein, human; abl1 protein; eutos long term survival score; molecular recurrence; sokal score; treatment free remission
|